future of glp 1 drugs Didn't take much for the time magazine to do a flip! From “The big promise” to “A metabolic whiplash” A new study came out yesterday that showed that stopping GLP-1 for GLP 1: Just a wonder

Potential Cardiovascular Benefits: Ongoing REDEFINE 3 trials are assessing whether CagriSema can reduce cardiovascular risks, a major concern for people with obesity or type 2 diabetes

Ref Type: Generic, Hubbard JS, Stadtman ER: Regulation of glutamine synthetase

Presented for research literature review only Mayer D et al

That was peripheral neuropathy

In the Phase 2 ACCESS II study, aleniglipron achieved clinically meaningful and statistically significant placebo-adjusted mean weight loss of 16.3% (39 lbs

At TOSM, we only use verified peptidessourced from FDA-registered compounding pharmaciesensuring quality, purity, and safety for our patients